Remove Drug Delivery Remove Insulin Remove Marketing Remove Vaccine
article thumbnail

Injectable Drug Delivery 2022

pharmaphorum

There is a rising demand for vaccines, insulin, and many modern medicines used to treat cancer and other chronic diseases. As biologics are mainly administered through the injectable route, the significant growth in the biologics market is expected to drive the injectable drug delivery and prefilled syringe market in the coming years.

article thumbnail

Phase 3 trial dashes Oramed’s oral insulin hopes

pharmaphorum

Oramed Pharma has conceded defeat in its attempt to bring an oral formulation of insulin to market for people with type 2 diabetes, after its ORMD-0801 candidate missed the mark in a phase 3 trial. The post Phase 3 trial dashes Oramed’s oral insulin hopes appeared first on.

Insulin 59
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Subcutaneous Biologics: The Unmet Requirement in the Pharmaceutical Space

Roots Analysis

However, several drug delivery devices that enable patients to self-administer their respective medications are now available. Subcutaneous biologics – current market landscape. Subcutaneous drug delivery systems – the helping hand for patients. Of these, 50 players have approved subcutaneous biologics.

article thumbnail

Pricing, Profits and Progress: Pharma’s Post-COVID Priorities

pharmaphorum

The need for firms to make a reasonable profit is paramount in today’s world; healthy pharmaceutical research and manufacturing are the keys to ending disease, curing chronic conditions, and discovering new therapies and vaccines that address the latest medical challenges.